Zyversa Therapeutics, Inc. ( (ZVSA) ) has released its Q4 earnings. Here is a breakdown of the information Zyversa Therapeutics, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing first-in-class drugs for renal and inflammatory diseases. The company recently reported its financial results for 2024, highlighting significant progress in its drug development pipeline. Key developments include the anticipated start of a Phase 2a clinical trial for VAR 200 in diabetic kidney disease patients and a Phase 1 trial for IC 100 in obesity-related conditions. Financially, ZyVersa reported a net loss of $9.4 million for 2024, a significant improvement from the previous year, largely due to reduced impairments. The company is actively seeking additional funding to support its ongoing operations and future milestones. Looking ahead, ZyVersa is optimistic about achieving value-building milestones in the next 12 months, driven by its advancing clinical trials and strategic initiatives.